Grifols Sa (GRFS) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Grifols Sa  (NASDAQ: GRFS)


Grifols Sa's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Grifols Sa's ROI in the fourth quarter of 2025?
Grifols Sa achieved a return on average invested assets (ROI) of 2.83 % in its fourth quarter of 2025, which is below Grifols Sa's average return on investment, which stands at 3.22%.

ROI has improved compared to 1.18% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 218 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 2171.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM -8.08 % -5.23 % -3.04 % -0.83 % 1.38 %
Y / Y Net Income Change TTM 134.96 % 17.79 % 17.79 % 17.79 % 17.79 %
Investment (TTM) in Millions 19,816 19,816 19,816 19,816 21,559
Return On Investment (TTM) 2.83 % 1.18 % 1.15 % 1.13 % 1.11 %
GRFS's Overall Ranking # 2171 # 0 # # #
Seq. Investment Change TTM -2.15 % -2.11 % -2.06 % -2.02 % 0.88 %
Seq. Net Income Change TTM 134.96 % 0 % 0 % 0 % 17.79 %
Net Income (TTM) in Millions 560 238 238 238 238

GRFS Company Profile >> Back to GRFS Roi Comparisons >> See Annual GRFS Return On Investment



Return On Investment GRFS's Ranking
Within: No.
Industry # 79
Sector # 219
Overall # 2171

Return On Investment Statistics
High Average Low
6.06 %
3.22 %
0.94 %
(Dec 31 2017)   (Dec 31 2023)



  News about Grifols Sa Return on Investment ROI

Yimmugo's $1 Billion Sales Projection in the US Fuels Grifols' Expansion, but Efforts Need to Boost ROI for Sustained Growth

July 1, 2024



Grifols, a leading global producer of plasma-derived medicines, has announced that its subsidiary, Biotest, anticipates generating approximately $1 billion in revenue from sales of its intravenous immunoglobulin (Ig) called Yimmugo over the next seven years in the United States. This positive forecast follows the recent approval by the Food and Drug Administration (FDA), allowing Yimmugo to be used in the treatment of primary immunodeficiencies (PID). However, despite this promising development, Grifols Sa s return on average invested assets (ROI) for the fourth quarter of 2023 was reported to be 0.94%, falling below its average ROI of 3.94%. This article will outline the facts and assess the impact of these developments on the company s future prospects.
Factual Analysis:
1. Biotest s Yimmugo Sales Forecast: The announcement by Grifols highlights Biotest s optimism in achieving significant sales success in the United States, projecting approximately $1 billion in revenue from Yimmugo sales over the next seven years. This forecast is based on the recent FDA approval for the treatment of PID, indicating strong potential for Biotest in the immunoglobulin market.

Grifols Sets New Strategic Path with Sale of Equity Stake and Alliance with Haier Group

June 18, 2024


The agreement between Grifols and Haier Group signifies a significant development in the healthcare industry, with implications for both companies future growth and expansion. The deal has successfully obtained all necessary regulatory approvals and compliance confirmation from the Shenzhen Stock Exchange.
Grifols achieved a return on average invested assets (ROI) of 0.94% in its fourth quarter of 2023, a figure that falls below its average return on investment of 3.94%. This discrepancy in performance raises questions about the motivations behind the sale of the equity stake and the potential impact of the strategic alliance with Haier Group on Grifols overall profitability and growth trajectory.





Financial Statements
Grifols Sa's IV. Quarter Investments $ 19,816 Millions GRFS's Balance sheet
Grifols Sa's IV. Quarter Income $ 560 Millions Quarterly GRFS's Income Statement
GRFS's Income by Division See GRFS's Income by Division


GRFS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 19,816 21,559 21,421 21,928 17,651
Y / Y Investment Growth -8.08 % 0.65 % -2.31 % 24.23 % 13.06 %
Net Income in Millions 560 238 202 304 297
Y / Y Net Income Growth 134.96 % 17.79 % -33.37 % 2.19 % -62.58 %
Annual Return On Investment 2.83 % 1.11 % 0.94 % 1.38 % 1.68 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 2.83 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GRFS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GRFS's Competitors
Subscribers only: Roi for Grifols Sa's Suppliers
Subscribers only: Return On Investment for GRFS's Customers

Other Ratios
GRFS's Roa GRFS's Inventory Turnover Ratio GRFS's Growth Rates GRFS's Dividend Statistics
GRFS's Profitability Ratios GRFS's Asset Turnover Ratio GRFS's Dividend Growth
GRFS's Roe GRFS's Valuation Ratios GRFS's Financial Strength Ratios GRFS's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Stryker Corp  7.73 %
Phibro Animal Health Corporation  7.64 %
Tactile Systems Technology Inc   7.64 %
Addus Homecare Corp  7.34 %
Steris Plc  7.30 %
Hologic Inc  7.26 %
Xtant Medical Holdings Inc   7.24 %
Davita Inc   7.14 %
Kamada Ltd   7.05 %
Ani Pharmaceuticals Inc  6.97 %
Concentra Group Holdings Parent Inc   6.84 %
Amphastar Pharmaceuticals Inc   6.77 %
Gyre Therapeutics Inc   6.75 %
Abbvie Inc   6.64 %
Cadre Holdings inc   6.53 %
Talkspace Inc   6.31 %
Arcutis Biotherapeutics Inc   6.01 %
Royalty Pharma Plc  5.98 %
Smith and Nephew Plc  5.98 %
Iqvia Holdings Inc   5.94 %
Beone Medicines Ltd   5.86 %
Community Health Systems Inc   5.80 %
Medtronic Plc  5.79 %
Ensign Group Inc  5.56 %
Labcorp Holdings Inc   5.52 %
Organogenesis Holdings Inc   5.48 %
Collegium Pharmaceutical Inc   5.39 %
Merit Medical Systems Inc  5.38 %
Amneal Pharmaceuticals Inc   5.34 %
Ardent Health Inc   5.22 %

Date modified: 2026-06-22T16:58:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.